GLP-1 eating disorder risk is subtype-specific: protective for binge eating disorder but potentially harmful for restrictive eating disorders through the same appetite suppression mechanism

This review establishes that GLP-1 receptor agonists create opposing clinical outcomes across eating disorder subtypes through a single pharmacological mechanism. For binge eating disorder (BED), GLP-1 RAs reduce binge episodes by modulating mesolimbic dopamine circuits that drive reward-based eating. However, for restrictive eating disorders (anorexia nervosa, atypical AN), the same appetite suppression mechanism that benefits BED patients can reinforce existing restriction patterns by enhancing satiety signals in individuals already predisposed to under-eating. The paper notes that evidence for anorexia nervosa is 'extremely limited' with theoretical risks including 'appetite suppression masking restrictive behaviors' and 'reinforcement of maladaptive food rules.' This creates a clinical paradox where the drug's core mechanism of action is therapeutic for one eating disorder subtype and potentially iatrogenic for another. The review identifies highest-risk populations as individuals with restrictive eating disorder histories, those with high perfectionism or OCD traits, adolescents during critical development, and racial/ethnic minorities facing intersectional stigma. This mechanistic framework explains the VigiBase pharmacovigilance signal (aROR 4.17-6.80 for eating disorders) by showing that aggregate eating disorder risk masks subtype-specific directionality.

Extending Evidence

Source: PMC/Journal of Clinical Medicine systematic review, 2025

2025 case documented: woman with childhood anorexia prescribed tirzepatide for metabolic indications reignited restrictive patterns, overexercise, and secret continued dosing after physician stopped prescription. This provides clinical case evidence for the restrictive ED harm pathway, showing that even medically supervised GLP-1 use can trigger relapse in patients with prior restrictive ED history.

Supporting Evidence

Source: NBC News 2024-08-15

Clinicians describe progression from beneficial appetite suppression to pathological restriction, with 'atypical anorexia nervosa' pattern emerging. Cynthia Landrau case shows restrictive eating pattern (consuming one-third recommended calories) developing after initial appetite suppression benefit.

Extending Evidence

Source: Northwestern Medicine JCI 2025, Dr. Beutler

Northwestern's AgRP neuron silencing mechanism provides the neurological explanation for subtype-specific risk. For restrictive eating disorders (anorexia nervosa, atypical anorexia), semaglutide removes the AgRP-mediated biological alarm that would normally trigger compensatory hunger during dangerous weight loss. For binge eating disorder, the same mechanism may be protective by reducing the hedonic drive to eat. The 'double whammy' of fullness signaling PLUS starvation-protection removal creates asymmetric risk profiles across ED subtypes.

Supporting Evidence

Source: NPR, behavioral health specialist interviews

Dr. DeCaro and Dr. Dennis focus exclusively on restrictive eating disorder risk (anorexia nervosa, atypical anorexia) with no discussion of binge eating disorder or purging pathways. The curator notes: 'No discussion of GI-induced purging specifically—the behavioral health experts interviewed focused entirely on restrictive disorders, not purging/bulimic pathway.' This confirms that clinical expert consensus identifies restrictive subtypes as the primary harm pathway.

Supporting Evidence

Source: Sa et al., Diabetes Obesity and Metabolism 2026

Review finds GLP-1RAs 'show promise for REDUCING binge eating' with improvements in BES scores (-8.14 points vs. controls), while simultaneously noting 'caution is warranted in individuals with anorexia nervosa or restrictive eating patterns.' This confirms subtype-specific divergence: protective for BED, potentially harmful for restrictive subtypes.